SCHEMBL2815052

SCHEMBL2815052

CNc1nc2ccccc2n2c(-c3ccc(O)cc3)cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.47
IKBKB O14920 6/20 0.46
CHUK O15111 3/20 0.46
TOP2A P11388 1/20 0.44
USP7 Q93009 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
ADORA2A P29274 2/20 0.39
ADORA1 P30542 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LCK P06239 1/20 0.39
BCHE P06276 1/20 0.38
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
LMNA P02545 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895220 0.90 IKBKB (0.49) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2816677 0.90 HTR2C (0.51) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2818724 0.88 IKBKB (0.48) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2816389 0.88 HTR2C (0.47) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2818464 0.88 HTR2C (0.47) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL17895199 0.87 IKBKB (0.46) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2815160 0.87 IKBKB (0.47) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2815092 0.86 IKBKB (0.46) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2817059 0.85 MAPT (0.47) HTR2CIKBKBCHUKTOP2ASMN1; SMN2
SCHEMBL2820446 0.84 IKBKB (0.46) HTR2CIKBKBCHUKTOP2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP claimed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US claimed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS HTR2C 1292/4885IKBKB 855/4885CHUK 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.